Cellectis S.A. (CLLS) vs Genelux (GNLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Genelux (GNLX) has outperformed Cellectis S.A. (CLLS) over the past year, losing 57.7% versus a loss of 73.9%. Genelux is the larger company by market cap ($109.5 million vs $104.8 million), about 1.0 times the size, while Cellectis S.A. is growing revenue faster (+75.8% vs +0.0%). Cellectis S.A. converts more of its revenue into profit, with a net margin of -92.7% versus -401812.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | GNLX |
|---|---|---|
| Share price | $1.04 | $2.42 |
| Market cap | $104.76M | $109.49M |
| 1-day change | -5.88% | -2.42% |
| YTD return | -78.51% | -44.50% |
| 1-year return | -73.87% | -57.69% |
| 5-year return | -90.34% | — |
| EPS (TTM) | $-0.64 | $-0.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.95M | $8.00K |
| Revenue growth (YoY) | +75.76% | 0.00% |
| Net income (latest FY) | $-67.59M | $-32.15M |
| Gross margin | 100.00% | — |
| Operating margin | -45.34% | -415175.00% |
| Net margin | -92.66% | -401812.50% |
| 52-week high | $5.45 | $8.54 |
| 52-week low | $1.03 | $2.29 |
| Distance from 52-week high | -80.92% | -71.65% |
| Analyst consensus | none | none |
| Avg. price target upside | +364.42% | +678.10% |
| Average volume | 86.69K | 288.93K |
| Shares outstanding | 72.73M | 45.25M |
| Employees | 224 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GNLX has outperformed CLLS by 16.2 percentage points over the past year.
- Cellectis S.A. is more profitable, keeping -92.7 cents of every revenue dollar as net income versus -401812.5 cents for Genelux.
- Cellectis S.A. grew revenue faster in its latest fiscal year (+75.76% vs 0.00%).
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
CLLS vs GNLX FAQ
Which is bigger, Cellectis S.A. or Genelux?
Genelux (GNLX) is larger, with a market capitalization of $109.49M compared with $104.76M for Cellectis S.A. (CLLS).
Which stock has performed better over the past year, CLLS or GNLX?
GNLX returned -57.69% over the past 12 months, compared with -73.87% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Genelux in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.